Sign in to fuzzto save your conversations, follow your research and come back anytime.
Panacea Biotec
SectorHealthcare
In the news
Panacea Biotec crashes 9.99% leading BSE 'B' group losers
Panacea Biotec shares surge 60% in 6 days on dengue vaccine project
Panacea Biotec surges 56% in 6 sessions on DENSTAR dengue vaccine trial
Panacea Biotec's DENSTAR project launches June 1, 2026 for African dengue vaccine licensure
Panacea Biotec posts ₹0.52 cr Q4 profit vs ₹1.89 cr loss last year
Panacea Biotec shares surge 6% on dengue vaccine milestone
Company insights, generated from the most recent coverage.
DengiAll vaccine is in Phase 3 trials (10,335 participants), expected launch 2028-29+ — trailing Qdenga by 2-3 years, limiting near-term competitive threat to Dr. Reddy's exclusive window.